» Articles » PMID: 34174442

Controlling CRISPR with Small Molecule Regulation for Somatic Cell Genome Editing

Overview
Journal Mol Ther
Publisher Cell Press
Date 2021 Jun 26
PMID 34174442
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Biomedical research has been revolutionized by the introduction of many CRISPR-Cas systems that induce programmable edits to nearly any gene in the human genome. Nuclease-based CRISPR-Cas editors can produce on-target genomic changes but can also generate unwanted genotoxicity and adverse events, in part by cleaving non-targeted sites in the genome. Additional translational challenges for in vivo somatic cell editing include limited packaging capacity of viral vectors and host immune responses. Altogether, these challenges motivate recent efforts to control the expression and activity of different Cas systems in vivo. Current strategies utilize small molecules, light, magnetism, and temperature to conditionally control Cas systems through various activation, inhibition, or degradation mechanisms. This review focuses on small molecules that can be incorporated as regulatory switches to control Cas genome editors. Additional development of CRISPR-Cas-based therapeutic approaches with small molecule regulation have high potential to increase editing efficiency with less adverse effects for somatic cell genome editing strategies in vivo.

Citing Articles

Engineered Cas9 variants bypass Keap1-mediated degradation in human cells and enhance epigenome editing efficiency.

Chen J, Su S, Pickar-Oliver A, Chiarella A, Hahn Q, Goldfarb D Nucleic Acids Res. 2024; 52(19):11536-11551.

PMID: 39228373 PMC: 11514467. DOI: 10.1093/nar/gkae761.


MiRNA-Responsive CRISPR-Cas System via a DNA Regulator.

Yun D, Jung C Biosensors (Basel). 2023; 13(11).

PMID: 37998150 PMC: 10669420. DOI: 10.3390/bios13110975.


Recent Updates on Corticosteroid-Induced Neuropsychiatric Disorders and Theranostic Advancements through Gene Editing Tools.

Singh M, Agarwal V, Jindal D, Pancham P, Agarwal S, Mani S Diagnostics (Basel). 2023; 13(3).

PMID: 36766442 PMC: 9914305. DOI: 10.3390/diagnostics13030337.


The CRISPR-Cas system as a tool for diagnosing and treating infectious diseases.

Lou J, Wang B, Li J, Ni P, Jin Y, Chen S Mol Biol Rep. 2022; 49(12):11301-11311.

PMID: 35857175 PMC: 9297709. DOI: 10.1007/s11033-022-07752-z.


Tailoring Cardiac Synthetic Transcriptional Modulation Towards Precision Medicine.

Schoger E, Lelek S, Panakova D, Zelarayan L Front Cardiovasc Med. 2022; 8:783072.

PMID: 35097003 PMC: 8795974. DOI: 10.3389/fcvm.2021.783072.


References
1.
Meszaros B, Kumar M, Gibson T, Uyar B, Dosztanyi Z . Degrons in cancer. Sci Signal. 2017; 10(470). DOI: 10.1126/scisignal.aak9982. View

2.
Cyranoski D . CRISPR gene-editing tested in a person for the first time. Nature. 2016; 539(7630):479. DOI: 10.1038/nature.2016.20988. View

3.
Cox D, Platt R, Zhang F . Therapeutic genome editing: prospects and challenges. Nat Med. 2015; 21(2):121-31. PMC: 4492683. DOI: 10.1038/nm.3793. View

4.
McClure C, Hassan A, Aughey G, Butt K, Estacio-Gomez A, Duggal A . An auxin-inducible, GAL4-compatible, gene expression system for . Elife. 2022; 11. PMC: 8975555. DOI: 10.7554/eLife.67598. View

5.
Hac-Wydro K, Flasinski M . The studies on the toxicity mechanism of environmentally hazardous natural (IAA) and synthetic (NAA) auxin--The experiments on model Arabidopsis thaliana and rat liver plasma membranes. Colloids Surf B Biointerfaces. 2015; 130:53-60. DOI: 10.1016/j.colsurfb.2015.03.064. View